Author: dcade

Home > Articles by: dcade
print share

Bio-Process Systems Alliance (BPSA) Appoints Three New Members to Its Scientific Advisory Council

Sept. 17, 2026 (ARLINGTON, VA)– The Bio-Process Systems Alliance (BPSA) recently announced the appointment of three industry leaders to its Scientific Advisory Council (SAC) at the 2026 BPSA International Single-Use Summit, held in July in Boston, MA. The new SAC members are Nelly Montenay of Sartorius, Heidi Sinkovich of Meissner, and Aidan Sexton, PhD, of Johnson & Johnson.

Formed in 2021, the BPSA SAC provides technical direction for the Alliance and supports the development of scientifically grounded resources that advance the adoption and use of single-use technologies. Chaired by BPSA Second Vice Chair, Kirsten Strahlendorf of Sanofi, the SAC oversees BPSA’s technical portfolio, including white papers and other technical projects, and helps guide responses to technical questions from across the bioprocessing community. “We are pleased to welcome Nelly, Heidi, and Aidan to the Scientific Advisory Council,” said Mark Petrich, PhD, of Krystal Biotech & BPSA Chair. “Each brings deep technical expertise and a strong track record of leadership in single-use bioprocessing innovation and manufacturing excellence. Their perspectives will strengthen BPSA’s work in supporting and advancing the safe, scalable, and sustainable use of single-use technologies.”

New Scientific Advisory Council Members

Nelly Montenay is Head of PD Science & Testing at Sartorius. An engineer in polymer sciences, she leads global teams focused on materials science, testing, and scientific advocacy for single-use systems. She has driven initiatives in flexible materials, irradiation strategies, and sustainability, and is also an active contributor to BioPhorum and ECI single-use conferences.

Heidi Sinkovich is Director of Applications Engineering at Meissner Corporation. She leads global engineering teams supporting biopharmaceutical customers and has expertise in sterilization validation and ISO standards. Sinkovich also contributes to ASTM International and ASME BPE standards and has authored industry guidance on particulate control in single-use systems.

Aidan Sexton, PhD, is Senior Principal Scientist, Materials Sciences at Johnson & Johnson Innovative Medicine. With more than 30 years in the industry, he specializes in materials science, validation, and manufacturing support. Sexton has also contributed to multiple BioPhorum best practice guidelines on extractables and leachables and serves in advisory roles, including the ELSIE Board of Directors.

___________________________________________________

About BPSA

The Bio-Process Systems Alliance is an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, best practice sharing, development of consensus guides, and networking opportunities among its member companies. For more information, visit www.bpsalliance.org.

Home > Articles by: dcade
print share

BPSA 2026 International Single-Use Summit Showcases Future of Bioprocessing

Industry focused on innovation, resilience, and collaboration to support growth

Aug 6, 2026 (ARLINGTON, VA)– The single-use bioprocessing industry is operating in a more normalized post-pandemic environment, with companies focused on growth, innovation, emerging technologies, automation and artificial intelligence, manufacturing flexibility, and the role single-use technologies will play as new modalities-including cell therapies, gene therapies, and other advanced biopharmaceutical therapies-continue to mature.

Those priorities shaped discussions at the 2026 BPSA International Single-Use Summit, held July 27–29 at the Fairmont Copley Plaza in Boston, MA, USA. Hosted by the Bio-Process Systems Alliance (BPSA), the international association representing the single-use bioprocessing industry, the Summit brought together suppliers, end users, pharmaceutical and biotechnology professionals, and key industry partners. This year marked the first time BPSA brought the Summit to Boston, where the event drew record attendance and connected the global single-use community with one of the world’s leading regions for biopharmaceutical innovation and manufacturing. The strong turnout also reflected BPSA’s continued member engagement and momentum following the association’s 20th anniversary in 2025.

The conversations come at a pivotal time for the industry. Several major market research firms point to continued strong growth in the global single-use bioprocessing market over the next decade. While exact projections vary, many expect the market to roughly double, driven by rising demand for biologics, vaccines, cell therapies, gene therapies, and other advanced modalities.

“BPSA’s Summit has always been where BPSA members and the single-use community come together to discuss the issues that matter most to our industry,” said Chris Clark, Executive Director of BPSA. “Single-use technologies now sit at the center of modern biopharmaceutical manufacturing. What we heard in Boston is that the industry is using these technologies strategically to improve efficiency, support enabling technologies, strengthen quality, and advance innovation. Ultimately, this work supports a larger goal: helping ensure that critical therapies continue reaching patients and consumers around the world,” Clark added.

BPSA extends its appreciation to the 2026 Summit co-chairs, David Radspinner of VintaBio and Brendan Lucey of Kivi Bio, for helping shape this year’s program. BPSA also recognizes Bürkert Fluid Control Systems as the exclusive Welcome Reception Sponsor and thanks its sustaining sponsors, including AdvantaPure, Bürkert Fluid Control Systems, CPC Biotech, Cytiva, Entegris, MilliporeSigma, PendoTECH, RENOLIT Healthcare Solutions, Saint-Gobain, Sartorius, and Solvias, for their ongoing support.

BPSA membership is open to organizations of every size across the single-use value chain-component and material suppliers, equipment manufacturers, pharmaceutical manufacturers, CDMOs, testing and service providers, and other biotechnology companies. Members help shape the industry’s technical guidance and standards, gain early access to BPSA working groups and publications, and connect directly with the end users specifying single-use systems.

About BPSA

Bio-Process Systems Alliance (BPSA) is an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, best practice sharing, and networking opportunities among its member companies.

Home > Articles by: dcade
print share

BPSA Publishes Two New Papers Highlighting the Role of Single-Use Technologies in Cell & Gene Therapy and Continuous Bioprocessing

The Bio-Process Systems Alliance (BPSA) is pleased to announce the publication of two new technical papers focused on advancing the implementation of single-use technologies across biopharmaceutical manufacturing. The new resources address manufacturing bottlenecks in cell and gene therapy production and the growing adoption of continuous bioprocessing.

The first paper, Navigating Cell and Gene Therapy Manufacturing Bottlenecks, examines common constraints that impact the scalability and reliability of cell and gene therapy manufacturing. The paper highlights how single-use technologies address operational bottlenecks and support flexible and efficient manufacturing strategies in this rapidly evolving sector.

The second paper, Continuous Bioprocessing with Single-Use Technologies, explores how single-use systems support the transition from traditional batch processing to continuous manufacturing. This paper provides a practical overview of key considerations, challenges, and opportunities for integrating single-use technologies into continuous operations.

“These two papers focus on areas that are at the center of innovation and growth across bioprocessing,” said BPSA Chair, Mark Petrich, PhD, of Krystal Biotech. “Single-use technologies continue to play a critical role both in addressing the unique challenges of cell and gene therapy manufacturing and in enabling more flexible approaches to continuous bioprocessing. These BPSA papers provide valuable insights for single-use suppliers and end-users alike.”

“I would like to thank the BPSA Advanced Therapies Committee, co-chaired by Brendan Lucey of Kivi Bio LLC and Todd Pangburn, PhD of Dupont, and the BPSA Continuous Bioprocessing Committee, co-chaired by David Chau, PhD of Thermo Fisher Scientific and Davinder Chawla, PhD, of Sanofi, for their dedication and contributions.”

The papers are now available for download:

Navigating Cell and Gene Therapy Manufacturing Bottlenecks – Download
Continuous Bioprocessing with Single-Use Technologies – Download

Visit BPSA’s resource library for additional information.

Special thanks to BPSA sustaining sponsors: AdvantaPure, Burkert Fluid Control Systems, Cytiva, CPC Biotech, Entegris, MilliporeSigma, PendoTECH, Renolit Healthcare, Saint-Gobain Life Sciences, Sartorius and Solvias for making these resources possible.

Home > Articles by: dcade
print share

Bio-Process Systems Alliance Announces 2026 – 2027 Board Election Results

December 11, 2025, 2025 (ARLINGTON, VA) – The Bio-Process Systems Alliance (BPSA), the international association for the single-use bioprocessing industry, has announced its newly elected Board members for the 2026–2027 term.

Todd Andrews, Global Director of Application and Business Development, Biopharma at CPC, was re-elected as Secretary for a second two-year term. Ravi Narayanan, Commercial Vice President, Fluid Management & Flexibles at DuPont Healthcare Solutions, was re-elected as Treasurer for a second two-year term. Andrews has more than 20 years of experience in the single-use biopharma industry, focusing on connection technology, and has been an active BPSA member for over 15 years. Narayanan brings over 20 years of experience serving the biopharma and medical device industries and has previously led global product management for biopharma single-use components at Nordson Medical.

Two new Directors-at-Large were elected for two-year terms: Sade Mokuolu, PhD, Regional Business Development and Marketing Manager at Watson-Marlow Fluid Technology Solutions (WMFTS), and Brian Horowski, Director, Process Technologist at IPS. Mokuolu has held a range of senior business and technical positions, including strategy implementation lead, global regulatory and validation services manager, and actively contributes to multiple industry workstreams. Horowski has more than 20 years of experience in facility design for bulk drug substance manufacturing, including monoclonal antibodies, recombinant proteins, gene therapies, and vaccines.

Additionally, Monica Cardona (MilliporeSigma), Brian Chung (Syensqo), Dianne Heiler (Repligen Corporation), John Puglia, PhD (Thermo Fisher Scientific), and Thomas Vandromme (Meissner) were re-elected as Directors-at-Large for two-year terms (2026–2027).

“Congratulations to Todd and Ravi on their re-election as Secretary and Treasurer. I appreciate that they have volunteered to continue managing significant roles in our organization,” said BPSA Chair Mark Petrich of Krystal Biotech, Inc. “I also congratulate all our new and returning Board members. Their extensive experience and leadership will be essential in guiding the Alliance forward. On behalf of the BPSA, I offer a special thanks to Jayanthi Grebin of JLG Life Science LLC and Chris Wilkins, PhD, of Filtration Group for their invaluable contributions as Directors-at-Large as their terms conclude this year.” Petrich continued, “For more than 20 years, BPSA has facilitated the growth of single-use technologies and contributed to their implementation in critical biopharmaceutical manufacturing operations. Single-use technologies are important tools in the quest to improve the health of patients and consumers. I look forward to working with this talented board of directors to address opportunities and needs in our industry.”

BPSA Executive Board Officers:
Chair: Mark Petrich, PhD, Krystal Biotech
1st Vice Chair: Todd Kapp, Kivi Bio, LLC
2nd Vice Chair: Kirsten Strahlendorf, Sanofi
Secretary: Todd Andrews, CPC
Treasurer: Ravi Narayanan, DuPont

At-Large Directors (newly elected through 2027):
Brian Horowski, IPS
Sade Mokuolu, PhD, Watson-Marlow

At-Large Directors (continuing through 2026/2027):
Monica Cardona, MilliporeSigma
Brian Chung, Syensqo
Ralph Daumke, PendoTECH
Patrick Evrard, Cytiva
Dianne Heiler, Repligen Corporation
Charlotte Masy, PhD, GSK
Hernán Parma, RENOLIT Healthcare
John Puglia, PhD, Thermo Fisher Scientific
Stuart Tindal, EngD, PhD, Sartorius
Thomas Vandromme, Meissner
Ping Wang, PharmD, Johnson & Johnson

Board members are elected by BPSA’s general membership to serve staggered two-year terms. They establish governing policies, determine budget priorities, and set strategic goals to advance the Alliance and its mission of supporting the single-use bioprocessing industry globally. Click here for a complete list of BPSA Board of Directors.

About BPSA:  An affiliate of SOCMA, The Bio-Process Systems Alliance (BPSA), is an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, best practice sharing, and networking opportunities among its member companies. For more information, visit www.bpsalliance.org.